Cargando…
The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
Currently, our world is facing the 2019 Novel Coronavirus (COVID-19) outbreak and tremendous efforts are made for developing drugs to treat and vaccines to prevent the disease. At present, there is no specific antiviral drug or vaccine for COVID-19. The pathogenic infectivity of the virus requires t...
Autores principales: | Belen-Apak, F.B., Sarialioglu, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169882/ https://www.ncbi.nlm.nih.gov/pubmed/32335456 http://dx.doi.org/10.1016/j.mehy.2020.109743 |
Ejemplares similares
-
Low molecular weight heparin versus unfractioned heparin for anticoagulation during perioperative extracorporeal membrane oxygenation: A single center experience in 102 lung transplant patients
por: Gratz, Johannes, et al.
Publicado: (2020) -
A randomized clinical trial of unfractioned heparin for treatment of sepsis (the HETRASE study): design and rationale [NCT00100308]
por: Jaimes, Fabián, et al.
Publicado: (2006) -
Favorable Outcomes of Anticoagulation With Unfractioned Heparin in Sepsis-Induced Coagulopathy: A Retrospective Analysis of MIMIC-III Database
por: Peng, Jiang-Chen, et al.
Publicado: (2022) -
Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin
por: Ertan-Bolelli, Tugba, et al.
Publicado: (2022) -
Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy
por: Belen-Apak, F. Burcu, et al.
Publicado: (2020)